Dr. Bidadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19 Bradhurst Ave
Hawthorne, NY 10532Phone+1 914-594-2222Fax+1 914-594-2221
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pediatric Hematology/Oncology, 2012 - 2015
- MedStar Health/Georgetown University HospitalResidency, Pediatrics, 2009 - 2012
- Tufts University School of MedicineClass of 2009
Certifications & Licensure
- NY State Medical License 2015 - 2017
- MN State Medical License 2012 - 2016
Publications & Presentations
PubMed
- 9 citationsPembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head ...Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara
The Lancet. Oncology. 2024-05-01 - 36 citationsPembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, Makoto Tahara, Lisa Licitra
Future Oncology. 2020-06-01 - 17 citationsPathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.Behzad Bidadi, Duan Liu, Krishna R. Kalari, Matthias Rübner, Alexander Hein
Frontiers in Pharmacology. 2018-03-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: